News

Patients’ Depression Often Carries Over to Care Partners

More disability and higher levels of depression in Parkinson’s disease patients predicted an increase in burden and depression of their care partners, such as family and friends, over two years, a study concluded. The findings underscore the need to monitor the burden of care partners over time. Treatment targeting disease severity,…

Brain Training App Useful in Early Parkinson’s Cases: Pilot Study

The cognitive exercise smartphone app NeuroNation, which combines personalized tasks and gamification, is useful and feasible for adults with mild Parkinson’s disease, a pilot study concluded. The researchers noted the app was a success in terms of the patients’ perception of its usability and in achieving cognitive improvements,…

Brain Ultrasound Signals Linked to Motor Disability, Gait

Enhanced ultrasound signals in the substantia nigra, the area of the brain impacted by Parkinson’s disease, are associated with increased motor disability and gait disturbances, a study concluded. The researchers noted that these ultrasound signals, called hyperechogenicity, may be useful a biomarker that reflects disease severity. “Our results may…

Citric Acid CQDs Shown to Protect Dopaminergic Neurons in Models

Nanomaterials with potent antioxidant properties called carbon quantum dots prevented Parkinson’s disease-related neurodegeneration in nerve cells and a worm model, a study reported. These antioxidants, especially those derived from citric acid — a common and nontoxic biochemical — may represent a new treatment approach for Parkinson’s and other neurodegenerative diseases,…

Pedaling for Parkinson’s Viewed Favorably by Patients in Study

People with Parkinson’s disease reported enjoying and benefiting physically and emotionally from a community cycling program — Pedaling for Parkinson’s (PFP) — viewing it favorably in a survey regardless of their age or disease symptoms and severity, a study of patients at five PFP sites reported. The aerobic program’s cost, access…

Koneksa Wins MJFF Grant to Investigate Digital Biomarkers

Koneksa has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to investigate the potential of digital biomarkers to evaluate and predict disease progression in people with Parkinson’s disease. Digital biomarkers have the potential to aid in diagnosing Parkinson’s and allowing patients…

Trial Failure of Antibody Targeting Alpha-synuclein Detailed

Treatment with prasinezumab, a monoclonal antibody designed to break up toxic alpha-synuclein aggregates, failed to slow the progression of Parkinson’s disease in a Phase 2 clinical trial. “In this placebo-controlled trial, treatment with prasinezumab, a humanized monoclonal antibody targeting aggregated [alpha]-synuclein, had no meaningful effect on global clinical or…